翰宇药业
(300199)
| 流通市值：167.86亿 | | | 总市值：199.08亿 |
| 流通股本：7.45亿 | | | 总股本：8.83亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 688,286,621.3 | 299,145,924.16 | 966,352,079.7 | 683,122,870.45 |
| 营业总成本 | 497,605,941.78 | 209,222,759.88 | 886,483,321.15 | 607,896,350.24 |
| 其他经营收益 | | | | |
| 营业利润 | 252,992,955.08 | 137,327,081.76 | 69,094,703.27 | 92,272,455.41 |
| 利润总额 | 253,755,196.3 | 136,892,344.09 | 64,229,892.83 | 87,613,673.41 |
| 净利润 | 235,639,855.52 | 127,394,823.1 | 34,026,010.77 | 69,758,073.47 |
| 每股收益 | | | | |
| 其他综合收益 | -469,687.5 | -267,945.47 | -1,258,380.34 | -841,191.83 |
| 综合收益总额 | 235,170,168.02 | 127,126,877.63 | 32,767,630.43 | 68,916,881.64 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 738,062,111.09 | 659,311,893.59 | 523,558,133.66 | 565,088,980.79 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,814,246,251.44 | 2,708,255,927.99 | 2,630,416,890.12 | 2,605,557,791.33 |
| 资产总计 | 3,552,308,362.53 | 3,367,567,821.58 | 3,153,975,023.78 | 3,170,646,772.12 |
| 流动负债: | | | | |
| 流动负债合计 | 1,602,580,594.48 | 1,537,922,310.66 | 1,781,723,048.38 | 1,516,680,236.88 |
| 非流动负债: | | | | |
| 非流动负债合计 | 1,084,572,488.4 | 1,072,533,521.66 | 742,324,363.77 | 987,889,672.4 |
| 负债合计 | 2,687,153,082.88 | 2,610,455,832.32 | 2,524,047,412.15 | 2,504,569,909.28 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 850,239,797.84 | 741,555,431.56 | 613,951,823.3 | 649,150,598.16 |
| 股东权益合计 | 865,155,279.65 | 757,111,989.26 | 629,927,611.63 | 666,076,862.84 |
| 负债和股东权益合计 | 3,552,308,362.53 | 3,367,567,821.58 | 3,153,975,023.78 | 3,170,646,772.12 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 778,555,824.91 | 309,022,877.48 | 967,372,030.19 | 799,866,415.7 |
| 经营活动现金流出小计 | 473,096,470.06 | 238,591,585.63 | 733,468,521.91 | 529,167,240.51 |
| 经营活动产生的现金流量净额 | 305,459,354.85 | 70,431,291.85 | 233,903,508.28 | 270,699,175.19 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 3,740,079.6 | 310,000 | 8,123,618.46 | 7,780,425.68 |
| 投资活动现金流出小计 | 213,875,188.11 | 82,827,936.48 | 234,796,112.95 | 173,272,458.81 |
| 投资活动产生的现金流量净额 | -210,135,108.51 | -82,517,936.48 | -226,672,494.49 | -165,492,033.13 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,045,564,926.66 | 910,165,621.1 | 1,828,066,818.02 | 1,107,100,971.04 |
| 筹资活动现金流出小计 | 1,099,910,353.84 | 885,453,666.03 | 1,852,029,183.85 | 1,189,769,767.06 |
| 筹资活动产生的现金流量净额 | -54,345,427.18 | 24,711,955.07 | -23,962,365.83 | -82,668,796.02 |
| 汇率变动对现金及现金等价物的影响 | -3,718,791.01 | -1,487,542.24 | 1,481,256.88 | 1,935,223.65 |
| 现金及现金等价物净增加额 | 37,260,028.15 | 11,137,768.2 | -15,250,095.16 | 24,473,569.69 |
| 期末现金及现金等价物余额 | 114,542,776.15 | 88,420,516.2 | 77,282,748 | 117,006,412.85 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 37,260,028.15 | - | -15,250,095.16 | - |